Latent Infection and Tuberculosis Disease in Rheumatoid Arthritis Patients
Section snippets
Epidemiology of latent tuberculosis infection and tuberculosis disease
The World Health Organization (WHO) estimates that approximately one third of the world's population, or approximately 2 billion people, are latently infected with Mycobacterium tuberculosis, the causative agent of tuberculosis. In 2006 the WHO reported a global incidence of 139 per 100,000 population, indicating that more than 1 million people develop active tuberculosis disease every year and approximately 2 million die as a result. Approximately every 20 minutes, 64 people die of
The Life Cycle of Mycobacterium tuberculosis in Infected Individuals
The immune response mounted to the infection generally is successful in containing, although not eliminating, the pathogen; thus, the infection becomes latent. M tuberculosis becomes dormant, residing in granulomas; as a result, infected individuals are asymptomatic and noninfectious.6 This latency often extends throughout a lifetime. Reactivation of latent tuberculosis infections (LTBIs), however, can occur in response to perturbations of the immune response, with active tuberculosis ensuing.
Tuberculosis and rheumatoid arthritis
New drug classes have been developed over the past 10 years based on human or chimeric antibodies against cytokines or receptors with pivotal roles in the inflammatory pathways of immune-mediated inflammatory disease. These agents are collectively referred to as biologics. Anti–TNF-α agents carry the largest infection risk of all the biologics, predisposing patients to mycobacterial infections. This is not surprising, as TNF has an important role in granuloma formation and maintenance, which is
Aging, rheumatoid arthritis, and the response of the immune system to Mycobacterium tuberculosis infection
Aging is a physiologic process that occurs over time in every living being and that is characterized by structural and functional changes at the cellular, organ, and system levels. The aging of the immune system, a process known as immunosenescence, usually parallels chronologic age; however, in autoimmune diseases, such as RA, this process can accelerate, resulting in further dysregulation of the immune system.46 This dysregulation in turn contributes to an increase susceptibility to
Latent Tuberculosis Infection in Patients who have Rheumatoid Arthritis
The cases of tuberculosis that occur in patients who have RA and are receiving anti–TNF-α therapy are, for the most part, the result of the reactivation of LTBI,51 which makes its diagnostic and treatment compulsory. The diagnosis begins with an adequate clinical history to detect the presence of risk factors predisposing to the development of tuberculosis. Even though the radiologic findings of granulomatous diseases are not specific, and abnormalities in LTBI are detected in only 10% to 20%
Screening test for tuberculosis before the initiation of biologic therapy in patients who have rheumatoid arthritis: current recommendations
Several countries have generated national guidelines that address LTBI before TNF-α blocker therapy is initiated, and these should be consulted.58 There are some notable differences between countries, which probably reflect local prevalence and other conditions of care.
Similar to any other diagnostic test, the predictive value of the IGRAs results depends on the prevalence of M tuberculosis infection in the population being tested. Results should be interpreted in conjunction with other
Nontuberculosis mycobacterial disease in patients undergoing anti–tumor necrosis factor α therapy
NTM infections are caused a group of more than 100 species of bacteria that are ubiquitous in soil and water and which exhibit varied pathogenicity. NTM infections are opportunistic, requiring defects in local or systemic host immunity to cause disease in humans. Unlike tuberculosis, disease from NTM infection is due to exposure to environmental organisms; cases of human-to-human transmission have never been documented.65 Patients who have pre-existing structural lung disease are known to be at
Summary
Patients receiving biologic therapies are at higher risk for developing tuberculosis than patients who have similar diseases and are not receiving these treatments or the general population; a definite risk exists particularly with anti-TNF agents. All patients who are candidates for the use of biologic agents should be screened for latent and active tuberculosis before its initiation. Despite a considerable reduction in the incidence of tuberculosis after initiation of anti-TNF therapy
Acknowledgments
The authors are grateful to Graciela S. Alarcón, MD, MPH, for her comments and suggestions in an earlier version of this article and for her help editing the English version.
References (77)
- et al.
Chemokines and tuberculosis
Cytokine Growth Factor Rev
(2003) Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection
Curr Opin Immunol
(2005)- et al.
Cytokine/chemokine cascades in immunity to tuberculosis
Immunol Today
(1999) - et al.
Lymphocyte subtype in experimentally induced early-stage bovine tuberculous lesions
J Comp Pathol
(2001) - et al.
The biological functions of T helper 17 cell effectors cytokines in inflammation
Immunity
(2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial
Lancet
(2008)IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?
Cytokines
(2008)- et al.
IL-23 and IL-17 in tuberculosis
Cytokines
(2008) - et al.
Immunosenescence, autoimmunity, and rheumatoid arthritis
Exp Gerontol
(2003) - et al.
Analysis of immunosenescence markers in patients with autoimmnune disease
Clin Immunol
(2007)
Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis
Chest
Fatal pulmonary nontuberculous mycobacterial infection in a patient receiving etanercept for rheumatoid arthritis
Chest
Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use
Diagn Microbiol Infect Dis
Prehistoric tuberculosis in America: adding comments to literature review
Mem Inst Oswaldo Cruz
[Tuberculosis as emergent diseases associated to medical treamtment of rheumatoid arthritis.]
Global tuberculosis control
Global epidemiology of tuberculosis: prospects for control
Semin Respir Crit Care Med
Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally
JAMA
Latent Mycobacterium tuberculosis persistence, patience, and winning by waiting
Nat Med
Immunology of tuberculosis
Annu Rev Immunol
Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium
Infect Immun
Role of tumor necrosis factor-alpha in Mycobacterium- induced granuloma formation in tumor necrosis factor alpha- deficient mice
Lab Invest
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology
Infect Immun
Interferon-γ: an overview of signals, mechanisms and functions
J Leukoc Biol
Cellular responses to interferon-γ
Annu Rev Immunol
Susceptibility to nontuberculous mycobacterial lung disease
Eur Respir J
IL-23 and IL-17 in the establishment of protective pulmonary CD4 (+) T cell responses after vaccination and during Mycobacterium tuberculosis challenge
Nat Immunol
Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice
Immunology
Interleukin-6 and interleukin-12 participate in induction of a type 1 protective T-cell response during vaccination with a tuberculosis subunit vaccine
Infect Immun
Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection
Infect Immun
B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis
J Immunol
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report
Arthritis Rheum
Increased risk of tuberculosis in patients with rheumatoid arthritis
J Rheumatol
Clinical characteristics of Mycobacterium in rheumatoid arthritis patients
Mod Rheumatol
Elevated risk of tuberculosis in patients with rheumatoid arthritis in Japan
Ann Rheum Dis
[Risk of tuberculosis disease in rheumatoid arthritis patients.]
Anales de la Facultad de Medicina de Montevideo
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy
Arthritis Rheum
Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers
J Rheumatol
Cited by (17)
Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
2020, Handbook of Systemic Autoimmune DiseasesCitation Excerpt :The greater association of active TB with anti-TNF antibody-treated patients caused by disruption of the granuloma is consistent with the lack of effectiveness of soluble TNF receptor etanercept in granulomatous diseases such as sarcoidosis or Crohn's disease [51,53]. Current biologic drugs that target CD4+T cells, B cells and IL-6, the main host mechanisms of protection against Mycobacterium tuberculosis, are likely to increase susceptibility to the reactivation of LTBI in patients [45]. An increased rate of reactivation of LTBI has been reported in RCTs with tocilizumab and abatacept, and to a much lesser extent with rituximab [54].
Risk management for prescribing biological therapies
2016, Revista Colombiana de ReumatologiaOld enemy on a difficult terrain: Tuberculosis in rheumatology practice with focus on uncommon extrapulmonary affection
2011, Indian Journal of RheumatologyIndian Rheumatology Association consensus statement on the diagnosis and treatment of axial spondyloarthropathies
2010, Indian Journal of Rheumatology